The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Bert H. O'Neil
No relevant relationships to disclose
Calin Cainap
No relevant relationships to disclose
Eric Van Cutsem
No relevant relationships to disclose
Vera A. Gorbunova
No relevant relationships to disclose
Christos Stelios Karapetis
No relevant relationships to disclose
Jordan Berlin
Consultant or Advisory Role - Abbott Laboratories; Sanofi
Research Funding - Abbott Laboratories
Richard M. Goldberg
Consultant or Advisory Role - Amgen; AstraZeneca; Genentech; GHI; Myriad Genetics
Research Funding - Abbott Laboratories; Amgen; Bayer; Genentech; Myriad Genetics; Sanofi
Qin Qin
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Jiang Qian
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Justin L. Ricker
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Mark D. McKee
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Dawn M. Carlson
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Tae Won Kim
No relevant relationships to disclose